Phase 2 Completed N=637 Randomized Double-blind Health Services Research

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Glaucoma · Open Angle or Ocular Hypertension

Source: ClinicalTrials.gov NCT03896633 ↗

Enrolled (actual)

637

Serious AEs

0.3%

Results posted

Jun 2021

Primary outcomePrimary: Intraocular Pressure (IOP) — 20.07; 19.89 mmHg

Summary

The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide compared with AzoptTM

Outcome Measures

Outcome	Result	p-value
PRIMARY Intraocular Pressure (IOP)	20.07; 19.89	—

Eligibility Criteria

Inclusion Criteria

Male and females 18 years of age or older,
diagnosed with primary open-angle glaucoma or ocular hypertension.

Exclusion Criteria

Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle glaucoma,
ocular hypertension.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03896633). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.